为您找到相关结果约363个

你是不是要搜索 期刊AZD9291耐药后 点击跳转

A case report of toxic epidermal necrolysis associated with AZD-9291

Circulating tumor cells predict prognosis following second-line AZD 9291 treatment in EGFR-T790M mutant

Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists

NEW AND CONVERGENT SYNTHESIS OF AZD 4547

Fatal interstitial lung disease associated with AZD9291

Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291

Structural Basis of AZD9291 Selectivity for EGFR T790M

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition

novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291(osimertinib) against AZD9291-resistant NSCLC cells with activated MET

AZD-9056, a P2X7 receptor inhibitor, suppresses ATP-induced melanogenesis

Resistance Mechanisms to AZD9291 and Rociletinib-Letter

Resistance Mechanisms to AZD9291 and Rociletinib-Response

Liquid Chromatography-Tandem Mass Spectrometric Assay for AZD9291 in Rat Plasma

Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells

AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells

为您找到相关结果约363个

共363条页码: 1/25页15条/页